Business & Industry
- ISTH: new data highlight innovation from Sanofi's pipeline in rare diseases
- Sevabertinib (BAY 2927088) granted FDA Priority Review for the treatment of patients with HER2-mutant non-small cell lung cancer
- Pfizer enters into exclusive licensing agreement with 3SBio
- Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years
- Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD
Research & Development
- Fighting myeloma with fiber: Plant-based diet offers promise
- Collaborations result in antibiotic resistance breakthrough
- Tea, berries, dark chocolate and apples could lead to a longer life span
- Application of machine learning in drug side effect prediction: databases, methods and challenges
- DeepSeek-R1 offers promising potential to accelerate healthcare transformation
- Researchers identify drug candidate for difficult-to-treat heart disease
- Potential new treatment for Alzheimer's disease, other neurodegenerative conditions
Conferences & Events
- New insights into T and B cells offer hope for autoimmune disease sufferers
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
Regulatory Affairs
- FDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
- FDA approves new treatment for hemophilia A or B
- FDA approves nasal spray influenza vaccine for self- or caregiver-administration
- FDA approves first nasal spray for treatment of anaphylaxis
- FDA approves nonsteroidal treatment for Duchenne muscular dystrophy